Successful screening for Gaucher disease in a high-prevalence population in tabuleiro do Norte (northeastern Brazil): a cross-sectional study.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  JIMD Reports

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/8904_2011_19PMID 23430831PMCID PMC3509821
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gaucher disease

  2019influential reference
• A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.

  2009cited by this paper
• Monitoring of Gaucher patients with a novel chitotriosidase assay.

  2007cited by this paper
• Imiglucerase (Cerezyme®) improves quality of life in patients with skeletal manifestations of Gaucher disease

  2007cited by this paper
• [Therapeutic objectives in Gaucher disease].

  2007cited by this paper
• Buts thérapeutiques dans la maladie de Gaucher

  2007cited by this paper
• The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.

  2006cited by this paper
• Twelve different enzyme assays on dried-blood filter paper samples for detection of patients with selected inherited lysosomal storage diseases.

  2006cited by this paper
• High frequency of mutation G377S in Brazilian type 3 Gaucher disease patients.

  2006cited by this paper
• Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders

  2006cited by this paper
• Principles of screening.

  2005cited by this paper
• Quality of life related to type 1 Gaucher disease: Spanish experience

  2005cited by this paper
• Gaucher disease: lessons from a decade of therapy.

  2004influential reference
• Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy.

  2004cited by this paper
• Newborn Screening for Lysosomal Storage Disorders: Clinical Evaluation of a Two-Tier Strategy

  2004cited by this paper
• Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening.

  2004cited by this paper
• Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention.

  2003cited by this paper
• Gaucher and Niemann-Pick diseases--enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards.

  2002cited by this paper
• Principles of screening.

  2001cited by this paper
• The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease.

  2000cited by this paper
• Gaucher disease: expression and characterization of mild and severe acid β-glucosidase mutations in Portuguese type 1 patients

  2000cited by this paper
• Mutation analysis of Gaucher disease using dot-blood samples on FTA filter paper.

  2000cited by this paper
• Quality of life assessment in adults with type 1 Gaucher disease

  1999cited by this paper
• The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study

  1998cited by this paper
• Gaucher disease: recommendations on diagnosis, evaluation, and monitoring.

  1998cited by this paper
• Type 1 Gaucher disease: Identification of N396T and prevalence of glucocerebrosidase mutations in the Portuguese

  1996cited by this paper
• Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype.

  1995cited by this paper
• Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

  1994cited by this paper
• Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs.

  1993cited by this paper
• Genetic diagnosis of Gaucher's disease.

  1992cited by this paper
• Misuse of marrow examination in the diagnosis of Gaucher disease.

  1990cited by this paper
• Differentiation of beta-glucocerebrosidase from beta-glucosidase in human tissues using sodium taurocholate.

  1976cited by this paper
• Differentiation of β-glucocerebrosidase from β-glucosidase in human tissues using sodium taurocholate

  1976cited by this paper
• Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease.

  1966cited by this paper

• Deficiency of Glucocerebrosidase Activity beyond Gaucher Disease: PSAP and LIMP-2 Dysfunctions

  2024cites this paper
• Disorders of Mitochondrial Carriers

  2022cites this paper
• Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1

  2022cites this paper
• Variable treatment response in a patient with pyridoxal N phosphate oxidase (PNPO) deficiency- understanding the paradox

  2020cites this paper
• Clusters of genetic diseases in Brazil

  2018cites this paper
• Achados oftalmológicos na doença de Gaucher tipo III: caso clínico

  2017cites this paper
• Ophthalmologic fndings in Gaucher’s disease type III: case report

  2017cites this paper
• Consanguinity and founder effect for Gaucher disease mutation G377S in a population from Tabuleiro do Norte, Northeastern Brazil

  2015cites this paper
• Screening of high-risk Gaucher disease patients in Brazil using miniaturized dried blood spots and leukocyte techniques.

  2012cites this paper